

## Nanexa presents at ISPOR Europe 2023

**Nanexa AB today announced that its scientific abstract has been accepted for the international health economic conference ISPOR Europe 2023, November 12-15, in Copenhagen, Denmark. The abstract is entitled "Association between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Search" and has been accepted as an oral podium presentation.**

"It is very encouraging that this abstract has been accepted for an international health economic scientific conference of this magnitude", said Bengt Gustavsson, Director of Clinical Development and Medical Affairs of Nanexa. "A Systematic Literature Review is always one of the cornerstones on which you build your health economical strategy. This strategy in turn leads to the price model used in future price negotiations with payers in different countries. We see from our data that adherence to drug treatments for multiple myeloma is not always as good as expected, that more research is needed in this particular area and that there is a need for a long-acting product like NEX-20 that can improve adherence to treatment."

### **For additional information, please contact:**

---

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: [david.westberg@nanexa.se](mailto:david.westberg@nanexa.se)

[www.nanexa.com](http://www.nanexa.com)

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

### **About Nanexa AB (publ)**

---

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

### **Attachments**

---

[Nanexa presents at ISPOR Europe 2023](#)